(Total Views: 763)
Posted On: 07/23/2020 9:15:50 AM
Post# of 153986
Re: clambottler #44690
Clamb,
I did listed to the shareholders CC. I’m not understanding the confusion here.
Dr. Pourhassan stated 64 reduction in SAEs, which there were (total number if SAEs rather than total number of patients with SAEs, which was 58%).
This was NOT OBVIOUSLY a safety trial. It was a trial of efficacy and safety, hence:
Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)
https://www.clinicaltrials.gov/ct2/show/NCT04...;load=cart
You wrote:
Big Claims Demand Big Proof
Claim: The # of patients suffering at least one SAE was reduced by > 50 % when taking Leronlimab
What part of SAEs is not about safety?
Read More: https://investorshangout.com/post/view?id=583...z6T1W4zg6J
I did listed to the shareholders CC. I’m not understanding the confusion here.
Dr. Pourhassan stated 64 reduction in SAEs, which there were (total number if SAEs rather than total number of patients with SAEs, which was 58%).
This was NOT OBVIOUSLY a safety trial. It was a trial of efficacy and safety, hence:
Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)
https://www.clinicaltrials.gov/ct2/show/NCT04...;load=cart
You wrote:
Big Claims Demand Big Proof
Claim: The # of patients suffering at least one SAE was reduced by > 50 % when taking Leronlimab
What part of SAEs is not about safety?
Read More: https://investorshangout.com/post/view?id=583...z6T1W4zg6J
(2)
(0)
